NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment
PRESS RELEASE Presentations outline how BluePrint® genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients’ benefit FLEX registry reinforces the clinical and real-world utility of MammaPrint® and BluePrint to Read More
Long-term Follow Up Data from Groundbreaking MINDACT Study Continues to Demonstrate Clinical Utility of MammaPrint
PRESS RELEASE Median follow up nearing 9 years confirms MINDACT as a positive de-escalation study IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MAY 29, 2020 – Agendia, Inc., a world leader in precision oncology Read More
Agendia to Showcase New Data at ASCO 2020 That Further Stratifies Breast Cancer Patients for More Precise Therapy Recommendations
PRESS RELEASE Data adds to the growing body of evidence demonstrating the efficacy of Agendia’s MammaPrint® and BluePrint® testing to consistently inform optimal breast cancer treatment planning IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences
PRESS RELEASE Development of MammaPrint®, first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment Irvine, California and Amsterdam, Netherlands, May 07, 2020 Read More
Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MARCH 31, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that Translational Cancer published long term analytical performance Read More
Agendia COVID-19 Statement
As a valued customer we wanted to reach out and assure you that we are monitoring the situation regarding the outbreak of Corona Virus Disease (COVID-19) very closely; your patient’s sample and the safety of Read More
Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020 IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 13, 2020 – Agendia, Read More
